Radiotherapy Does Not Influence the Severe Pulmonary Toxicity Observed With the Administration of Gemcitabine and Bleomycin in Patients With Advanced-Stage Hodgkin's Lymphoma Treated With the BAGCOPP Regimen: A Report by the German Hodgkin's Lymphoma Study Group

International Journal of Radiation Oncology Biology Physics

Volumn 70, Issue 1, 2008, Pages 161-165

  Macann, Andrew ^a   Bredenfeld, Henning ^b   Müller, Rolf Peter ^b   Diehl, Volker ^c   Engert, Andreas ^b   Eich, Hans Theodor ^b  

^a Auckland Regional Blood Centre   (New Zealand)

^b UNIVERSITY OF COLOGNE   (Germany)

^c German Hodgkin's Lymphoma Study Group   (Germany)

Author keywords

Gemcitabine; Hodgkin's lymphoma; Pneumonitis; Radiotherapy

Indexed keywords

ANTIBIOTICS; CHEMOTHERAPY; ONCOLOGY; PULMONARY DISEASES; TOXICITY;

GEMCITABINE; HODGKIN'S LYMPHOMA; PNEUMONITIS;

RADIOTHERAPY;

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG WITHDRAWAL; DYSPNEA; FATALITY; FEMALE; HODGKIN DISEASE; HUMAN; LUNG TOXICITY; MALE; MULTICENTER STUDY; PILOT STUDY; PLEURA EMPYEMA; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DOXORUBICIN; DRUG INTERACTIONS; ETOPOSIDE; FEMALE; GERMANY; HODGKIN DISEASE; HUMANS; LUNG; MALE; MIDDLE AGED; PILOT PROJECTS; PREDNISONE; PROCARBAZINE; REMISSION INDUCTION; VINCRISTINE;

EID: 37049028788     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.05.055     Document Type: Article

References (33)

1. Diehl V., Franklin J., Pfreundschuh M., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348 (2003) 2386-2395
2. Santoro A., Bredenfeld H., Devizze L., et al. Gemcitabine in the treatment of advanced Hodgkin's disease: Results of a multicenter phase II study. J Clin Oncol 18 (2000) 2615-2619
3. Lucas J., Horwitz S., Horning S., et al. Gemcitabine is active in relapsed Hodgkin's disease. J Clin Oncol 17 (1999) 2627-2628
4. Savage D., Rule S., Tighe M., et al. Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 11 (2000) 595-597
5. Friedberg J., Neuberg D., Kim H., et al. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: Unacceptable pulmonary toxicity. Cancer 98 (2003) 978-982
6. Bredenfeld H., Franklin J., Nogova L., et al. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: A report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 22 (2004) 2424-2429
7. Eich H.T., Müller R.P., Schneeweiss A., et al. Initiation of a teleradiotherapeutic network for patients in German lymphoma studies. Int J Radiat Oncol Biol Phys 58 (2004) 805-808
8. Seegenschmiedt M.H., and Sauer R. Systematik der akuten und chronischen Strahlenfolgen. Strahlenther Onkol 169 (1993) 83-95
9. Knobel H., Loge J., Lund M., et al. Late medical complications and fatigue in Hodgkin's disease survivors. J Clin Oncol 19 (2001) 3226-3233
10. Ng A., Li S., Recklitis C., et al. A comparison between long-term survivors of Hodgkin's disease and their siblings on fatigue level and factors predicting for increased fatigue. Ann Oncol 16 (2005) 1949-1955
11. Danson S., Blackhall F., Hulse P., et al. Interstitial lung disease in lung cancer. Drug Saf 28 (2005) 103-113
12. Barlesi F., Villani P., Doddoli C., et al. Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol 18 (2004) 85-91
13. Roychowdhury D., Cassidy C., Peterson P., et al. A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs 20 (2002) 311-315
14. Blackstock A., Lesser G., Fletcher-Steede J., et al. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 51 (2001) 1281-1289
15. Van Putten J., Price A., van der Leest A., et al. A phase I study of gemcitabine with concurrent radiotherapy in Stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 9 (2003) 2472-2477
16. Shewach D.S., and Lawrence T.S. Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 14 (1996) 257-263
17. Shewach D.S., Hahn T.M., Chang E., et al. Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54 (1994) 3218-3223
18. Lawrence T.S., Chang E.Y., Hahn T.M., et al. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro- 2'-deoxycytidine (Gemcitabine). Clin Cancer Res 3 (1997) 777-782
19. Gupta N., Ahmed I., Steinberg H., et al. Gemcitabine-induced pulmonary toxicity. Am J Clin Oncol 25 (2002) 96-100
20. Jeter M., Jänne P., Brooks S., et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Bio Phys 53 (2002) 394-400
21. Duggan D., Petroni G., Johnson J., et al. Randomised comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 21 (2003) 607-614
22. Smith L., Mendenhall N., Cicale M., et al. Results of a prospective study evaluating the effects of mantle irradiation on pulmonary function. Int J Radiat Oncol Biol Phys 16 (1989) 79-84
23. Watchie J., Coleman C., Raffin T., et al. Minimal long-term cardiopulmonary dysfunction following treatment for Hodgkin's disease. Int J Radiat Oncol Biol Phys 13 (1987) 517-524
24. Allavena C., Conroy T., Aletti P., et al. Late cardiopulmonary toxicity after treatment for Hodgkin's disease. Br J Cancer 65 (1992) 908-912
25. Martin W., Ristow K., Habermann T., et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 23 (2005) 7614-7620
26. Matthews J. Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin's disease: Possible synergy. Lancet 342 (1993) 998
27. Azoulay E., Herigault S., Levarne M., et al. Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis. Crit Care Med 31 (2003) 1442-1448
28. Wirth A., Prince H.M., Wolf M., et al. Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: A prospective Australasian Leukaemia and Lymphoma Study. Bone Marrow Transpl 35 (2005) 291-298
29. Theuws J., Muller S., Seppenwoolde Y., et al. Effect of radiotherapy and chemotherapy on pulmonary function after treatment for breast cancer and lymphoma: A follow-up study. J Clin Oncol 17 (1999) 3091-3100
30. Trott K., Herrmann T., and Kasper M. Target cells in radiation pneumopathy. Int J Radiat Oncol Biol Phys 58 (2004) 463-469
31. Theuws J., Kwa S., Wagenaar A., et al. Dose-effect relations for early local pulmonary injury after irradiation for malignant lymphoma and breast cancer. Radiat Oncol 48 (1998) 33-43
32. Engert A., Schiller P., Josting A., et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavourable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 19 (2003) 3601-3608
33. Blackstock A., Socinski M., Fitzgerald T., et al. Initial pulmonary toxicity evaluation of chemoradiotherapy (CRT) utilizing 74 Gy 3-dimensional (3-D) thoracic radiation in stage III non-small cell lung cancer (NSCLC): A cancer and leukemia group B (CALGB) randomized phase II trial. Int J Radiat Oncol Biol Phys 63 Suppl. (2005) S43